2013

Kidney injury molecule linked to chronic kidney disease

October 2, 2013

More than 15 years after the discovery of kidney injury molecule-1 (KIM-1) by Joseph Bonventre, MD, PhD, researchers in the HSCI Kidney Disease Program—of which Bonventre is a member—have found that the molecule promotes the scar tissue formation typically associated with chronic kidney disease, which affects approximately 9-10 percent of the world’s population. The finding was made in mice.... Read more about Kidney injury molecule linked to chronic kidney disease

Healthy stem cells generated from terminally ill patients with Pearson Marrow Pancreatic Syndrome

June 14, 2013

Using a difficult laboratory technique, HSCI physician-researchers have isolated genetically healthy stem cells from patients with Pearson Marrow Pancreas Syndrome (PS), a generally fatal infant blood disorder with less than a hundred reported cases worldwide. Children with PS experience a range of symptoms, most notably: anemia,...

Read more about Healthy stem cells generated from terminally ill patients with Pearson Marrow Pancreatic Syndrome

NHLBI Progenitor Cell Biology Consortium funding opportunity - due December 12, 2013

October 28, 2013

The NHLBI Progenitor Cell Biology Consortium (PCBC) is soliciting applications for Pilot Studies. NHLBI makes funds available for PCBC pilot studies to foster innovative, high-risk approaches with a potential for unusually high impact to advance the understanding of the biology of stem and progenitor cells significantly. Pilot studies will be supported for a maximum of two years at $100,000 direct costs per year. Pilot studies that bridge between two or more Consortium Research Hubs will be given higher priority in order to enhance the development of synergies between Consortium...

Read more about NHLBI Progenitor Cell Biology Consortium funding opportunity - due December 12, 2013

HSCI co-director Douglas Melton and Evotec collaborate on diabetes

November 6, 2013

Harvard Stem Cell Institute (HSCI) Co-director Douglas Melton, PhD, and Evotec AG have entered into their second research collaboration to find biological pathways and signals that could be therapeutically relevant to diabetic patients.

The objective of this new collaboration, dubbed “TargetEEM” (Target Enteroendocrine Mechanisms), is to screen disease-relevant animal models for novel pathways and targets that have the potential to repair mechanisms involved in insulin resistance and abnormal...

Read more about HSCI co-director Douglas Melton and Evotec collaborate on diabetes

Amy Wagers receives New York Stem Cell Foundation-Robertson Stem Cell Prize

October 15, 2013

The New York Stem Cell Foundation (NYSCF) announced today that Amy Wagers, PhD, Professor at Harvard University, will be the 2013 recipient of the NYSCF – Robertson Stem Cell Prize, which has been awarded since 2011 for extraordinary achievements in translational stem cell research by a younger scientist.

Dr. Wagers is the...

Read more about Amy Wagers receives New York Stem Cell Foundation-Robertson Stem Cell Prize

Pages